Contact Person: Raul A. Saavedra, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892–9529. 301–496–9223.

Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group, Neurological Sciences and Disorders A.

Date: February 16–17, 2003.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Sunspree Resort, 7601 East Indian Bend Road, Scottsdale, AZ 85250.

Contact Person: Richard D. Crosland, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd, Suite 3208, MSC 9529, Bethesda, MD 20892–9529. 301–496–9223.

Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group, Neurological Sciences and Disorders K.

Date: February 16–17, 2003.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Sunspree Resort, 7601 East Indian Bend Road, Scottsdale, AZ 85250.

Contact Person: Katherine M. Woodbury, PhD, Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd, Suite 3208, MSC 9529, Bethesda, MD 20892–9529. 301–496–9223.

Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group, Neurological Sciences and Disorders B.

Date: February 20–21, 2003.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Washington Monarch Hotel, 2401 M Street NW., Washington, DC 2037.

Contact Person: W. Ernest Lyons, PhD, Scientific Review Administrator, Scientific Review branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529 Bethesda, MD 20892–9529. 301–496–4056.

Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group, Neurological Sciences and Disorders C.

Date: February 20–21, 2003.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Monarch Hotel, 2401 M Street, NW., Washington, DC 20037.

Contact Person: Andrea Sawczuk, DDS, PhD, Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892–9529. 301–496–0660. *sawczuka@ninds.n.h.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: January 14, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03–1366 Filed 1–21–03; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Establishment of Medical Device User Fee Rates for Fiscal Year 2003 and Interim Procedures; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a correction notice that appeared in the **Federal Register** of January 10, 2003 (68 FR 1469). The document corrected a notice that appeared in the **Federal Register** of November 21, 2002 (67 FR 70228), which announced the rates and interim procedures for medical device user fees for fiscal year (FY) 2003. The November 21, 2002, document was inadvertently published with confusing language regarding the fee that must be paid by a small business that submits a 510(k) premarket notification for FDA review during FY 2003. The document intended to state that all 510(k)s submitted for FDA review during FY 2003 are subject to a standard fee of $2,187, and that all submitters who are subject to a fee, including a small business, are required to pay this fee. This document corrects the error in the correction notice.

ADDRESSES: Persons with access to the Internet may obtain further information on the Medical Device User Fee and Modernization Act of 2002 at http://www.fda.gov/cdrh/mdufma or http://www.fda.gov/cber/mdufma/mdufma.htm.

FOR FURTHER INFORMATION CONTACT: Frank Claunts, Office of Management and Systems (HFA–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4427.

SUPPLEMENTARY INFORMATION: In FR Doc. 03–494, appearing in the **Federal Register** of January 10, 2003, the following correction is made:

1. On page 1469, in the second column, at the bottom of the page, item 3 is revised to read ''On page 70229, in table 1, in the fourth column, in the last row, correct 'None in FY 2003' to read '2.187'.''

Dated: January 16, 2003.

Margaret M. Dotzel,

Assistant Commissioner for Policy.

[FR Doc. 03–1381 Filed 1–16–03; 3:21 pm]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program; Call for Public Comments on 10 Nominations, Proposed for Listing in the Report on Carcinogens, Eleventh Edition

Background

The National Toxicology Program (NTP) solicits final public comments on the nominations reviewed in 2002 for listing in the Report on Carcinogens, Eleventh Edition (''the Report''). This Report (previously known as the Annual Report on Carcinogens) is a Congressionally mandated listing of known human carcinogens and reasonably anticipated human carcinogens and its preparation is delegated to the National Toxicology Program by the Secretary, Department of Health and Human Services (DHHS). Section 301 (b) (4) of the Public Health Service Act, as amended, provides that the Secretary, (DHHS), shall publish a biennial report which contains a list of all substances (1) which either are known to be human carcinogens or may reasonably be anticipated to be human carcinogens; and (2) to which a significant number of persons residing in the United States (US) are exposed. The law also states that the reports should provide available information on the nature of exposures, the estimated number of persons exposed and the extent to which the implementation of Federal regulations decreases the risk to public health from exposure to these chemicals.

In 2002, ten nominations were reviewed for listing in the Eleventh Report. This review included two Federal and one non-government, scientific peer reviews and public comment and review. The three scientific review committees evaluated all available data relevant to the criteria for inclusion of candidate nominations in the Report. The criteria used in the review process and a detailed description of the review procedures, including the steps in the current formal review process, can be obtained from

the NTP home page Web site at *http://ntp-server.niehs.nih.gov/* or by contacting: Dr. C. W. Jameson, National Toxicology Program, Report on Carcinogens, MD EC–14, P.O. Box 12233, Research Triangle Park, NC 27709; phone: (919) 541–4096, fax: (919) 541–0144, e-mail: *jameson@niehs.nih.gov.*

Public Comment Requested

The nominations reviewed in 2002 are provided in the following table with their Chemical Abstracts Services (CAS) Registry numbers (where available) and the recommendations from the three scientific peer reviews. The NTP will be making a final recommendation for these ten nominations for listing in, or changing the current listing from *reasonably anticipated to be a human carcinogen* to the *known to be a human carcinogen* category in the Eleventh Report.

Background documents provided to the review committees and the public are available on the Internet in PDF-format at the address above. Hard copies of these documents are also available upon request from Dr. Jameson (contact information above). The NTP will review the recommendations from each of the review committees and consider the public comments received throughout the process in making decisions regarding the NTP recommendations to the Secretary, DHHS, for listing of the nominated substances in the Report on Carcinogens, Eleventh Edition. The NTP solicits final public comment to supplement any previously submitted comments or to provide comments for the first time on any substance in the following table. Comments will be accepted for 60 days from the publication date of this announcement and should be directed to Dr. C. W. Jameson at the address provided above. Individuals submitting public comments are asked to include relevant contact information [name, affiliation (if any), address, telephone, fax, e-mail, and sponsoring organization (if any)].

Dated: January 10, 2003.

Kenneth Olden,

Director, National Toxicology Program.

SUMMARY OF RG1,[1] RG2[2] AND NTP BOARD SUBCOMMITTEE[3] RECOMMENDATIONS FOR THE NOMINATIONS REVIEWED IN 2002 FOR LISTING IN THE REPORT ON CARCINOGENS,[4] 11TH EDITION

Nomination/CAS No.	Primary uses or exposures	RGI action	RG2 action	NTP board subcommittee action
1-Amino-2,4-dibromoanthraquinone/(81–49–2).	An anthraquinone-derived vat dye that is used in the textile industry.	Motion to list 1-amino-2,4-dibromoanthraquinone as reasonably anticipated to be a human carcinogen passed by unanimous vote (8/0).	Motion to list 1-amino-2,4-dibromoanthraquinone as reasonably anticipated to be a human carcinogen passed by unanimous vote (8/0).	Motion to list 1-amino-2,4-dibromoanthraquinone as reasonably anticipated to be a human carcinogen passed by unanimous vote (9/0)
Selected Heterocyclic Amines (three nominations): (1) MeIQ (2-Amino-3,4-dimethyl-imidazo- [4,5-f]quinoline)/* (77094–11–2) (2) MeIQx (2-Amino-3,8-dimethyl-imidazo[4,5-f] quinoxaline)/(77500–04–0) (3) PhIP (2-Amino-1-methyl-6-phenyl-imidazo[4,5-b]pyridine)/(105650–23–5)	MeIQ, MeIQx, and PhIP are heterocyclic amines that are formed during heating or cooking and are found in cooked meat and fish.	Motion to list MeIQ as reasonably anticipated to be a human carcinogen passed by unanimous vote (6/0).	Motion to list MeIQ as reasonably anticipated to be a human carcinogen passed by unanimous vote (8/0).	Motion to list MeIQ as reasonably anticipated to be a human carcinogen passed by a vote of 8 yes, 0 no and 1 abstention. Abstention because member felt insufficient data for human exposure to list in the RoC.
		Motion to list MeIQx as reasonably anticipated to be a human carcinogen passed by a vote of 5 yes to 1 no. Negative vote cast because member felt data meet criteria to list as known human carcinogen.	Motion to list MeIQx as reasonably anticipated to be a human carcinogen passed by unanimous vote (8/0).	Motion to list MeIQx as reasonably anticipated to be a human carcinogen passed by a unanimous vote (9/0).
		Motion to list PhIP as reasonably anticipated to be a human carcinogen passed by a vote of 5 yes to 1 no. Negative vote cast because member felt data meet criteria to list as known human carcinogen.	Motion to list PhIP as reasonably anticipated to be a human carcinogen passed by unanimous vote (8/0).	Motion to list PhIP as reasonably anticipated to be a human carcinogen passed by unanimous vote (9/0).

SUMMARY OF RG1,[1] RG2[2] AND NTP BOARD SUBCOMMITTEE[3] RECOMMENDATIONS FOR THE NOMINATIONS REVIEWED IN 2002 FOR LISTING IN THE REPORT ON CARCINOGENS,[4] 11TH EDITION—Continued

Nomination/CAS No.	Primary uses or exposures	RGI action	RG2 action	NTP board subcommittee action
Cobalt Sulfate/(10026–2401).	Cobalt sulfate is used in electroplating and electrochemical industries. It is also used as a coloring agent for ceramics, a drying agent in inks, paints, varnishes and linoleum, and has been added to animal feed as a mineral supplement.	Motion to list cobalt sulfate as reasonably anticipated to be a human carcinogen passed by unanimous vote (9/0).	Motion to list cobalt sulfate as reasonably anticipated to be a human carcinogen passed by a vote of 8 yes and 1 no. Negative vote cast because member felt exposure data in background document needed to be more specific for cobalt sulfate.	Motion to list cobalt sulfate as reasonably anticipated to be a human carcinogen passed by a vote of 8 yes to 1 no. Negative vote cast because member felt human exposure data not specific for cobalt sulfate.
Diethanolamine (DEA)/(111–42–2).	DEA is used in the preparation of surfactants used in liquid laundry, dishwashing detergents, cosmetics, shampoos, and hair conditioners; as a surface-active agent and corrosion inhibitor in metalworking fluids and as a dispersant in agricultural chemical formulations.	Motion *not* to list DEA in the RoC passed by a vote of 7 yes to 2 no. Negative votes cast because members felt data sufficient to list as reasonably anticipated to be a human carcinogen.	Motion *not* to list DEA in the RoC passed by unanimous vote (9/0).	Motion *not* to list DEA in the RoC passed by a vote of 8 yes to 1 no. Negative vote cost because member felt data sufficient to list as reasonably anticipated to be a human carcinogen.
Naphthalene (91–20–3)	Naphthalene is used as a intermediate in the synthesis of many industrial chemicals, and has been used as an ingredient in some moth repellants and toilet bowl deodorants, and to control lice on livestock and poultry.	Motion to list naphthalene as reasonably anticipated to be a human carcinogen passed by a vote of 6 yes to 1 no. Negative vote cast because member felt data not sufficient to list in the RoC.	The RG2 could not make a majority recommendation for either listing or not listing naphthalene in the RoC.	Motion to list naphthalene as reasonably anticipated to be a human carcinogen passed by unanimous vote (9/0).
Nitrobenzne (98–95–3)	Nitrobenzene is used mainly in the production of aniline, itself a major chemical intermediate in the production of dyes.	Motion to list nitrobenzene as reasonably anticipated to be a human carcinogen passed by unanimous vote (7/0).	Motion to list nitrobenzene as reasonably anticipated to be a human carcinogen passed by unanimous vote (7/0).	Motion to list nitrobenzene as reasonably anticipated to be a human carcinogen passed by unanimous vote (9/0).
Nitromethane (75–52–5) ...	Nitromethane is used in specialized fuels, in explosives and in the synthesis of nitromethane derivatives, pharmaceuticals, agricultural soil fumigants and industrial antimicrobials.	Motion to list nitromethane as reasonably anticipated to be a human carcinogen passed by unanimous vote (8/0).	Motion to list nitromethane as reasonably anticipated to be a human carcinogen passed by unaimous vote (9/0).	Motion to list nitromethane as reasonably anticipated to be a human carcinogen passed by unanimous vote (9/0).
4,4′-Thiodianiline (139–65–1).	4,4′-Thiodianiline has been produced commercially since the early 1940's as an intermediate of several diazo dyes.	Motion to list 4,4′-thiodianiline as reasonably anticipated to be a human carcinogen passed by a vote of 6 yes to 2 no. Negative votes cast because members felt there was not sufficient exposure to list in the RoC.	Motion to list 4,4′-thiodianiline as reasonably anticipated to be a human carcinogen passed by a vote of 6 yes to 3 no. Negative votes cast because members felt there was not sufficient exposure to list in the RoC.	Motion to list 4,4′-thiodianiline as reasonably anticipated to be a human carcinogen passed by a vote of 5 yes to 2 no with 2 abstentions. Negative votes and abstentions cast because members felt there was not sufficient exposure to list in the RoC.

[1] The NIEHS Review Committee for the Report on Carcinogens (RG1).
[2] The NTP Executive Committee* Interagency Working Group for the Report on Carcinogens (RG2).

*Agencies from NTP Executive Committee represented on RG2 include: Agency for Toxic Substances and Disease Registry (ATSDR), Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), National Center for Environmental Health of the Centers for Disease Control and Prevention (NCEH/CDC), National Center for Toxicological Research of the Food and Drug Administration (NCTR/FDA), National Institute for Occupational Safety and Health/CDC (NIOSH/CDC), Occupational Safety and Health Administration (OSHA), National Cancer Institute of the National Institutes of Health (NCI/NIH), and National Institute of Environmental Health Sciences/NIH (NIEHS/NIH).

[3] The NTP Board of Scientific Counselors Report on Carcinogens Subcommittee (the External Peer Review Group).

[4] RoC—Report on Carcinogens.

[FR Doc. 03–1368 Filed 1–21–03; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No.FR–4815–N–01]

Notice of Submission of Proposed Information Collection to OMB: Public Housing Agency—Lease Requirements, Recordkeeping Requirements

AGENCY: Office of the Chief Information Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: *Comments Due Date:* February 21, 2003.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number (2577–0006) and should be sent to: Lauren Wittenberg, OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503; Fax number (202)395–6974; e-mail *Lauren_Wittenberg@omb.eop.gov.*

FOR FURTHER INFORMATION CONTACT: Wayne Eddins, Reports Management Officer, AYO, Department of Housing and Urban Development, 451 Seventh Street, Southwest, Washington, DC 20410; e-mail *Wayne_Eddins@HUD.gov;* telephone (202) 708–2374. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Mr. Eddins.

SUPPLEMENTARY INFORMATION: The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. chapter 35). The notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the OMB approval number, if applicable; (4) the description of the need for the information and its proposed use; (5) the agency form number, if applicable; (6) what members of the public will be affected by the proposal; (7) how frequently information submissions will be required; (8) an estimate of the total number of hours needed to prepare the information submission including number of respondents, frequency of response, and hours of response; (9) whether the proposal is new, an extension, reinstatement, or revision of an information collection requirement; and (10) the name and telephone number of an agency official familiar with the proposal and of the OMB Desk Officer for the Department.

This notice also lists the following information:

Title of Proposal: Public Housing Agency—Lease Requirements, Recordkeeping Requirements.

OMB Approval Number: 2577–0006.

Form Numbers: None.

Description of the Need for the Information and Its Proposed Use: Public Housing Agencies (PHA) are required to keep records for implementation of Federal regulations governing dwelling leases in public housing. The information is retained by the PHAs that manage public housing and is used for operating purposes.

Respondents: Individuals or households, State, local or tribal government.

Frequency of Submission: Annually.

	Number of respondents	Annual responses	×	Hours per response	=	Burden hours
Reporting Burden	3,330	3,330		48		158,400

Total Estimated Burden Hours: 158,400.

Status: Reinstatement, without change.

Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended.

Dated: January 14, 2003.

Wayne Eddins,

Departmental Reports Management Officer, Office of the Chief Information Officer.

[FR Doc. 03–1274 Filed 1–21–03; 8:45 am]

BILLING CODE 4210–72–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Decision and Availability of Decision Documents on the Issuance of Permits for Incidental Take of Threatened and Endangered Species

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of decision.

SUMMARY: Between November 14, 2001, and November 22, 2002, Region 1 of the Fish and Wildlife Service (we, the Service) approved 11 Habitat Conservation Plans (HCPs) and associated permits for the incidental take of threatened and endangered species, pursuant to section 10(a)(1)(B) of the Endangered Species Act of 1973, as amended (Act). We also amended two HCPs and associated permits. In addition, we issued two permits for Safe Harbor Agreements and one permit for a Candidate Conservation Agreement with Assurances, pursuant to section 10(a)(1)(A) of the Act.

Copies of the permits and associated decision documents are available upon request. Charges for copying, shipping and handling may apply.

ADDRESSES: Documents are available from the Fish and Wildlife Service, 911 N.E. 11th Avenue, Portland, Oregon 97232.

FOR FURTHER INFORMATION CONTACT: If you would like copies of any of the above documents, please contact Shelly